{"disease":{"id":"pneumococcal-infections","name":"pneumococcal infections"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04841369","title":"Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3420,"lead_sponsor_name":"CanSino Biologics Inc.","has_results":false},{"nct_id":"NCT04945681","title":"Evaluating the Effectiveness of a Pneumococcal Immunisation Campaign in a Camp for Internally Displaced People","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2882,"lead_sponsor_name":"London School of Hygiene and Tropical Medicine","has_results":false},{"nct_id":"NCT03692871","title":"A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2409,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03950856","title":"Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2340,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT00427895","title":"Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2141,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05477693","title":"Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1800,"lead_sponsor_name":"Sinovac Biotech Co., Ltd","has_results":false},{"nct_id":"NCT05731115","title":"Lot-to-lot Consistency of 23-valent Pneumococcal Polysaccharide Vaccine","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1800,"lead_sponsor_name":"Sinovac Biotech Co., Ltd","has_results":false},{"nct_id":"NCT03893448","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1720,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03547167","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1515,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04664556","title":"Invasive Pneumococcal Disease Study","phase":"","overall_status":"RECRUITING","enrollment_count":1369,"lead_sponsor_name":"Association Clinique Thérapeutique Infantile du val de Marne","has_results":false},{"nct_id":"NCT06838000","title":"Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1268,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT03950622","title":"Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1205,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03615482","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04016714","title":"Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1191,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04031846","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1184,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT01215188","title":"A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1152,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06822907","title":"Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":1052,"lead_sponsor_name":"Centre Hospitalier Universitaire de Saint Etienne","has_results":false},{"nct_id":"NCT02987972","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1051,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05380193","title":"Serotype Distribution in Hospitalized Adult With Pneumococcal Community Acquired Pneumonia in France","phase":"","overall_status":"COMPLETED","enrollment_count":1017,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT03574389","title":"A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":936,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03620162","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":900,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04384107","title":"Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":694,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT01513551","title":"The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":692,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02547649","title":"Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":690,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03480763","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":652,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03885934","title":"Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":606,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04989465","title":"A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Sinovac Biotech Co., Ltd","has_results":false},{"nct_id":"NCT07017777","title":"A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"CanSino Biologics Inc.","has_results":false},{"nct_id":"NCT02201030","title":"Immunogenicity and Safety Study of NBP606 in Healthy Infants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":577,"lead_sponsor_name":"SK Chemicals Co., Ltd.","has_results":false},{"nct_id":"NCT03550313","title":"Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":565,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03276754","title":"Immunization To Prevent Acute COPD Exacerbations","phase":"","overall_status":"TERMINATED","enrollment_count":530,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03313050","title":"A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":511,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06608199","title":"A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Beijing Minhai Biotechnology Co., Ltd","has_results":false},{"nct_id":"NCT03552445","title":"Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":462,"lead_sponsor_name":"Korea University Guro Hospital","has_results":false},{"nct_id":"NCT02927444","title":"Immunogenicity and Safety Study of NBP606 in Healthy Toddlers","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":462,"lead_sponsor_name":"SK Chemicals Co., Ltd.","has_results":false},{"nct_id":"NCT03512288","title":"Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":460,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03313037","title":"Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":444,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03921424","title":"Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":407,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02225587","title":"Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05412030","title":"A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":388,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT02037984","title":"Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":341,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02531373","title":"A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":338,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05092386","title":"Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":310,"lead_sponsor_name":"Sinovac Life Sciences Co., Ltd.","has_results":false},{"nct_id":"NCT03480802","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":302,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03565900","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":277,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04875858","title":"Immunogenicity After Revaccination With 23-valent Pneumococcal Polysaccharide Vaccine: Healthy Elderly People Versus Diabetic Patients","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":254,"lead_sponsor_name":"Korea University Guro Hospital","has_results":false},{"nct_id":"NCT02573181","title":"Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":253,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04100772","title":"Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":237,"lead_sponsor_name":"CanSino Biologics Inc.","has_results":false},{"nct_id":"NCT05229081","title":"Impact of Pharmacist-led Educational Intervention on Pneumococcal Vaccination Rates in Cancer Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":228,"lead_sponsor_name":"Hacettepe University","has_results":false},{"nct_id":"NCT02787863","title":"Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":219,"lead_sponsor_name":"Mikhael Petrovich Kostinov","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}